Showing 1,801 - 1,820 results of 1,834 for search '"Shenzhen"', query time: 0.05s Refine Results
  1. 1801
  2. 1802
  3. 1803
  4. 1804
  5. 1805
  6. 1806
  7. 1807

    Significance of supervision sampling in control of communicable respiratory disease simulated by a new model during different stages of the disease by Alphonse Houssou Hounye, Xiaogao Pan, Yuqi Zhao, Cong Cao, Jiaoju Wang, Abidi Mimi Venunye, Li Xiong, Xiangping Chai, Muzhou Hou

    Published 2025-01-01
    “…Ultimately, we conducted simulations and predictions for other prominent cities in China, such as Wuhan, Shanghai, Guangzhou, and Shenzhen, that have recently been affected by the COVID-19 outbreak. …”
    Get full text
    Article
  8. 1808
  9. 1809
  10. 1810

    Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models by Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, Song S

    Published 2025-01-01
    “…Yi Liu,1– 4,* Xiao Wang,1– 3,5,* Ni Zhang,1– 4,* Simin He,1– 4 Jianping Zhang,1– 4 Xiaoping Xu,1– 4 Shaoli Song1– 4 1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Center for Biomedical Imaging, Fudan University, Shanghai, 200032, People’s Republic of China; 4Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, People’s Republic of China; 5State Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory & Center for Molecular Imaging and Translational Medicine, School of Public Health, Shenzhen Research Institute of Xiamen University, Xiamen University, Xiamen, 361102, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shaoli Song; Xiaoping Xu, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China, Email shaoli-song@163.com; xxp0012@ustc.eduPurpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits. …”
    Get full text
    Article
  11. 1811
  12. 1812
  13. 1813
  14. 1814
  15. 1815
  16. 1816
  17. 1817
  18. 1818
  19. 1819
  20. 1820